ETF Managers Group LLC raised its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 8.5% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,929 shares of the medical device company’s stock after buying an additional 151 shares during the quarter. ETF Managers Group LLC’s holdings in DexCom were worth $230,000 at the end of the most recent reporting period.
Several other hedge funds have also recently added to or reduced their stakes in DXCM. Legal & General Group Plc lifted its position in shares of DexCom by 42.6% during the third quarter. Legal & General Group Plc now owns 60,492 shares of the medical device company’s stock valued at $8,653,000 after buying an additional 18,075 shares during the last quarter. Vanguard Group Inc raised its position in shares of DexCom by 11.5% in the 3rd quarter. Vanguard Group Inc now owns 7,942,861 shares of the medical device company’s stock valued at $1,136,147,000 after purchasing an additional 816,247 shares during the last quarter. First Hawaiian Bank raised its position in shares of DexCom by 75.6% in the 4th quarter. First Hawaiian Bank now owns 395 shares of the medical device company’s stock valued at $47,000 after purchasing an additional 170 shares during the last quarter. Oakbrook Investments LLC purchased a new position in shares of DexCom in the 4th quarter valued at approximately $500,000. Finally, Meeder Asset Management Inc. raised its position in shares of DexCom by 2,167.0% in the 4th quarter. Meeder Asset Management Inc. now owns 2,267 shares of the medical device company’s stock valued at $272,000 after purchasing an additional 2,167 shares during the last quarter. 96.50% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ DXCM traded up $1.72 during midday trading on Friday, reaching $148.04. 1,192,029 shares of the stock were exchanged, compared to its average volume of 1,336,322. The stock has a market capitalization of $13.32 billion, a price-to-earnings ratio of 493.47 and a beta of 0.70. DexCom, Inc. has a twelve month low of $90.61 and a twelve month high of $156.16. The company has a debt-to-equity ratio of 1.57, a current ratio of 7.18 and a quick ratio of 6.75.
DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Wednesday, May 1st. The medical device company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.12. DexCom had a negative net margin of 11.51% and a positive return on equity of 8.45%. The business had revenue of $280.50 million for the quarter, compared to analysts’ expectations of $246.10 million. During the same quarter last year, the company earned ($0.30) EPS. The business’s revenue was up 52.1% on a year-over-year basis. Analysts anticipate that DexCom, Inc. will post 0.81 earnings per share for the current fiscal year.
DXCM has been the subject of several research analyst reports. Canaccord Genuity increased their price objective on shares of DexCom from $140.00 to $160.00 and gave the company a “buy” rating in a research report on Friday, February 22nd. Cowen increased their price objective on shares of DexCom from $150.00 to $175.00 and gave the company an “outperform” rating in a research report on Friday, February 22nd. Morgan Stanley increased their price objective on shares of DexCom from $135.00 to $160.00 and gave the company an “equal weight” rating in a research report on Monday, February 25th. BidaskClub lowered shares of DexCom from a “buy” rating to a “hold” rating in a research report on Tuesday, March 26th. Finally, ValuEngine lowered shares of DexCom from a “strong-buy” rating to a “buy” rating in a research report on Monday, April 1st. Four equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $150.65.
In other DexCom news, SVP Patrick Michael Murphy sold 400 shares of the firm’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $127.03, for a total value of $50,812.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Steven Robert Pacelli sold 3,596 shares of the firm’s stock in a transaction on Friday, March 22nd. The shares were sold at an average price of $140.04, for a total value of $503,583.84. The disclosure for this sale can be found here. Insiders sold a total of 62,234 shares of company stock worth $7,614,307 in the last three months. 1.80% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: This piece was posted by Sundance Herald and is the sole property of of Sundance Herald. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://sundanceherald.com/2019/06/14/etf-managers-group-llc-has-230000-holdings-in-dexcom-inc-dxcm.html.
DexCom Company Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Recommended Story: Understanding Compound Annual Growth Rate (CAGR)
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.